What's Happening?
Zai Lab has announced a global clinical trial collaboration with Amgen to evaluate a novel DLL3-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan, in combination with Amgen's IMDELLTRA. This collaboration aims to explore the potential of
this dual-targeting strategy in treating extensive-stage small cell lung cancer (ES-SCLC). Amgen will sponsor a global Phase 1b study, while Zai Lab retains full ownership of the ADC.
Why It's Important?
This collaboration represents a significant advancement in the treatment of small cell lung cancer, a highly aggressive and lethal form of cancer. The dual-targeting approach could enhance treatment efficacy and address resistance pathways, offering new hope for patients with limited options. The partnership between Zai Lab and Amgen underscores the importance of collaborative efforts in advancing cancer treatment and could pave the way for future innovations in oncology.
